Carvalho Ana Maria R S, Costa Lourena E, Salles Beatriz C S, Santos Thaís T O, Ramos Fernanda F, Lima Mariana P, Chávez-Fumagalli Miguel A, Silvestre Bruna T, Portela Áquila S B, Roatt Bruno M, Silveira Julia A G, Gonçalves Denise U, Magalhães-Soares Danielle F, Duarte Mariana C, Menezes-Souza Daniel, Coelho Eduardo A F
Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.
Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901 Belo Horizonte, Minas Gerais, Brazil.
Cell Immunol. 2017 Aug;318:42-48. doi: 10.1016/j.cellimm.2017.06.001. Epub 2017 Jun 8.
In the present study, a conserved Leishmania hypothetical protein, namely LiHypA, was evaluated for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans. This protein showed a high amino acid sequence homology between viscerotropic and cutaneotropic Leishmania species. An enzyme-linked immunosorbent assay (ELISA) was developed using the recombinant antigen (rLiHypA), in addition to the A2 protein and two parasite antigenic preparations, which were used as controls. Regarding human diagnosis, results showed that rLiHypA was more sensitive and specific than ELISA-L. braziliensis SLA in detecting both cutaneous or mucosal leishmaniasis patients, but not those from Chagas disease patients or healthy subjects. Regarding canine diagnosis, this recombinant antigen showed higher sensitivity and specificity values, as well as a perfect accuracy to identify asymptomatic and symptomatic visceral leishmaniasis (VL) in dogs, but not those from vaccinated animals or those developing babesiosis, ehrlichiosis, or Chagas disease. However, using the rA2 protein or L. braziliensis SLA as controls, significant cross-reactivity was found when these samples were used, hampering their sensitivity and specificity values for the diagnosis. In this context, LiHypA could be considered a candidate to be evaluated for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans.
在本研究中，对一种保守的利什曼原虫假定蛋白LiHypA进行了评估，用于犬类和人类内脏利什曼病及皮肤利什曼病的血清学诊断。该蛋白在内脏型和皮肤型利什曼原虫物种之间显示出高度的氨基酸序列同源性。除了用作对照的A2蛋白和两种寄生虫抗原制剂外，还使用重组抗原（rLiHypA）开发了一种酶联免疫吸附测定（ELISA）。关于人类诊断，结果表明，在检测皮肤或黏膜利什曼病患者时，rLiHypA比巴西利什曼原虫可溶性利什曼抗原（SLA）ELISA更敏感和特异，但对恰加斯病患者或健康受试者则不然。关于犬类诊断，这种重组抗原显示出更高的敏感性和特异性值，以及在识别犬类无症状和有症状内脏利什曼病（VL）方面的完美准确性，但对接种疫苗的动物或患巴贝斯虫病、埃立克体病或恰加斯病的动物则不然。然而，当使用rA2蛋白或巴西利什曼原虫SLA作为对照时，使用这些样本时发现了显著的交叉反应，这妨碍了它们用于诊断的敏感性和特异性值。在这种情况下，LiHypA可被视为一种候选物，用于评估犬类和人类内脏利什曼病及皮肤利什曼病的血清学诊断。
